Controversies in the Management of Advanced Ovarian Cancer

OncologyONCOLOGY Vol 25 No 10
Volume 25
Issue 10

Whether advanced ovarian cancer should be treated with neoadjuvant chemotherapy or primary debulking surgery is one of the most debated topics in gynecologic oncology.

Whether advanced ovarian cancer should be treated with neoadjuvant chemotherapy or primary debulking surgery is one of the most debated topics in gynecologic oncology. In their article "Cytoreductive Surgery for Advanced Ovarian Cancer: Quo Vadis?" Schorge and his coauthors provide an excellent review of issues surrounding the management of advanced ovarian cancer. Primary cytoreductive surgery has been the cornerstone of treatment of advanced ovarian cancer. Theoretically, cytoreductive surgery can mediate the adverse metabolic effects of a large tumor burden, decrease chemotherapy resistance, and thereby improve the chances of responding to adjuvant treatment. Survival is predicated on the amount of disease present after cytoreduction. The most important benefit is the inverse relationship between the amount of residual disease and subsequent survival outcome. Although optimal cytoreductive surgery is the most important prognostic factor, optimal cytoreduction cannot be achieved in all patients with advanced ovarian cancer. The achievable rate of optimal cytoreduction for advanced disease varies widely; in addition, there is considerable heterogeneity among definitions of what could be regarded as optimal surgical outcome. Numerous studies have shown that to increase rates of optimal cytoreduction often requires the incorporation of a variety of ablative techniques and extensive upper abdominal procedures.[1] These techniques cannot be applied to all patients irrespective of comorbidity and performance status.

Neoadjuvant chemotherapy (NACT) is sometimes utilized when optimal cytoreduction is not deemed possible, in older patients with multiple comorbities, and in patients with poor performance status. The theory behind NACT is that it reduces tumor load, which decreases the need for extensive surgery, thereby lowering the perioperative morbidity and increasing the chances of optimal cytoreduction. However, due to lack of reliable evidence, the efficacy of NACT has been repeatedly challenged. The value of debulking after induction chemotherapy has been extensively debated in the past few decades.

The major concern about neoadjuvant chemotherapy in the management of advanced-stage ovarian cancer has been the issue of survival. While most data suggest worse patient outcomes with NACT,[2] a more recent randomized trial by the European Organisation for Research and Treatment of Cancer (EORTC),[3] described in the Schorge et al review, showed similar outcomes for both studied approaches (NACT with interval debulking, or primary debulking).

Even though a survey of Society of Gynecologic Oncologists (SGO) members on the use of NACT as primary treatment for ovarian cancer revealed that they treated less than 10% of patients with NACT, 39% of the respondents indicated that they believed women with bulky upper abdominal disease on preoperative imaging would benefit from NACT.[4] The survey also showed that about 20% would perform interval debulking by minimally invasive techniques if there was no gross residual disease after NACT.

A substantial number of SGO members have adapted the use of intraperitoneal (IP) chemotherapy to complete the therapy for women with minimal residual disease after initial NACT and interval debulking. Further studies are needed to validate this approach. The National Cancer Institute of Canada Clinical Trials Group has developed a protocol for a randomized phase II/III study that will examine whether IP platinum/taxane–based chemotherapy benefits women who have received neoadjuvant chemotherapy before optimal surgical debulking.[5] A retrospective review of 44 patients treated with taxane/ platinum–based NACT followed by postoperative IP chemotherapy did not show the survival benefit associated with IP chemotherapy after optimal upfront surgery.[6]

In this paper, Schorge et al review the published data but do not provide clear guidelines to clinicians as to what the best approach should be. In the absence of data from well-designed, well-conducted phase III randomized trials, it is difficult to formulate such guidelines, and a more personalized approach to each patient may be necessary. There is no universally applicable clinical model that can predict which patients will undergo optimal cytoreduction. Abdomino-pelvic computed tomography along with CA 125 testing is used by many gynecologic oncologists to predict resectability, but both studies have been shown to have limitations. Bristow et al developed a predictive index that was able to correctly predict surgical outcome (optimal [< 1 cm] vs suboptimal residual disease status).[7] The specificity for the ability to identify patients who would undergo optimal debulking was 80%. The authors do agree that a laparoscopy-and in certain situations, exploratory laparotomy-provides certain advantages as a selection tool. Furthermore, surgical skills make a difference in the setting of more advanced disease and may result in higher rates of complete resection that may translate to better overall outcomes. A multicenter, randomized controlled trial is needed to resolve some of the controversies surrounding this topic. This trial should be designed to address critical issues, such as the definition of uniform selection criterion that can consistently identify patients with surgically unresectable disease, and it should also look into the complex interaction between patient-related characteristics, tumor biology, and operative expertise.

Financial Disclosure: The authors have no significant financial interest or other relationship with the manufacturers of any products or providers of any service mentioned in this article.



1. Eisenhauer EL, Abu-Rustum NR, Sonoda Y, et al. The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer. Gynecol Oncol. 2006;103:1083-90.

2. Bristow RE, Chi DS. Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis. Gynecol Oncol. 2006;103:1070-6.

3. Vergote I, Tropé CG, Amant F, et al. European Organization for Research and Treatment of Cancer-Gynaecological Cancer Group; NCIC Clinical Trials Group. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010;363:943-53.

4. Dewdney SB, Rimel BJ, Reinhart AJ, et al. The role of neoadjuvant chemotherapy in the management of patients with advanced stage ovarian cancer: survey results from members of the Society of Gynecologic Oncologists. Gynecol Oncol. 2010;119:18-21.

5. Mackay HJ, Provencheur D, Heywood M, et al. Phase II/III study of intraperitoneal chemotherapy after neoadjuvant chemotherapy for ovarian cancer: NCIC CTG OV.21. Curr Oncol. 2011;18:84-90.

6. Le T, Latifah H, Jolicoeur L, et al. Does intraperitoneal chemotherapy benefit optimally debulked epithelial ovarian cancer patients after neoadjuvant chemotherapy? Gynecol Oncol. 2011;121:451-4. Epub 2011 Mar 12.

7. Bristow RE, Duska LR, Lambrou NC, et al. A model for predicting surgical outcome in patients with advanced ovarian carcinoma using computed tomography has been reported. Cancer. 2000;89:1532-40.

Related Videos
Guidelines from the Society of Gynecologic Oncology may help with managing the ongoing chemotherapy shortage in the treatment of patients with gynecologic cancers, according to Brian Slomovitz, MD, MS, FACOG.
Interim data reveal favorable responses in patients with low-grade serous ovarian cancer treated with avutometinib plus defactinib, according to Susana N. Banerjee, MD.
Brian Slomovitz, MD, MS, FACOG, notes that sometimes there is a need to substitute cisplatin for carboplatin, and vice versa, to best manage gynecologic cancers during the chemotherapy shortage.
Findings from the phase 3 MIRASOL trial support mirvetuximab soravtansine as a standard treatment option for platinum-resistant ovarian cancer, according to Ritu Salani, MD.
Trastuzumab deruxtecan appears to elicit ‘impressive’ responses among patients with HER2-positive gynecologic cancers regardless of immunohistochemistry in the phase 2 DESTINY-PanTumor02 trial.
Ritu Salani, MD, highlights the possible benefit of a novel targeted therapy and autologous tumor vaccine in patients with platinum-resistant ovarian cancer, and in the maintenance setting after treatment for platinum-sensitive disease.
In addition to potentially moving mirvetuximab into earlier lines of treatment for those with platinum-sensitive ovarian cancer, Ritu Salani, MD, also discusses combining the agent with carboplatin to decrease toxicities and improve quality of life.
Treatment with mirvetuximab soravtansine appears to produce a 3-fold improvement in objective response rate vs chemotherapy among patients with folate receptor-α–expressing, platinum-resistant ovarian cancer in the phase 3 MIRASOL trial.